
Archene A. Turner
Examiner (ID: 16553, Phone: (571)272-1545 , Office: P/1784 )
| Most Active Art Unit | 1784 |
| Art Unit(s) | 1794, 1315, 1774, 1508, 3722, 1784, 1775, 1317, 2775 |
| Total Applications | 2889 |
| Issued Applications | 2398 |
| Pending Applications | 65 |
| Abandoned Applications | 430 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20262901
[patent_doc_number] => 12433869
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Preventing and treating malaria
[patent_app_type] => utility
[patent_app_number] => 17/605025
[patent_app_country] => US
[patent_app_date] => 2020-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 20
[patent_no_of_words] => 23012
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605025
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605025 | Preventing and treating malaria | Apr 20, 2020 | Issued |
Array
(
[id] => 16222647
[patent_doc_number] => 20200247763
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
[patent_app_type] => utility
[patent_app_number] => 16/852810
[patent_app_country] => US
[patent_app_date] => 2020-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 86372
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16852810
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/852810 | Androgen receptor modulators and methods for their use | Apr 19, 2020 | Issued |
Array
(
[id] => 17718934
[patent_doc_number] => 20220211653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH
[patent_app_type] => utility
[patent_app_number] => 17/604508
[patent_app_country] => US
[patent_app_date] => 2020-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6358
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604508
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/604508 | COMPOSITIONS AND METHODS FOR INHIBITING BLOOD CANCER CELL GROWTH | Apr 19, 2020 | Pending |
Array
(
[id] => 17178293
[patent_doc_number] => 11155525
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-26
[patent_title] => Azole derivatives as apelin receptor agonist
[patent_app_type] => utility
[patent_app_number] => 16/853604
[patent_app_country] => US
[patent_app_date] => 2020-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30644
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16853604
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/853604 | Azole derivatives as apelin receptor agonist | Apr 19, 2020 | Issued |
Array
(
[id] => 16206481
[patent_doc_number] => 20200239471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => SYNTHESIS OF COELENTERAZINE
[patent_app_type] => utility
[patent_app_number] => 16/851962
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20861
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851962
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/851962 | Synthesis of coelenterazine | Apr 16, 2020 | Issued |
Array
(
[id] => 17306321
[patent_doc_number] => 11207404
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Compositions and uses
[patent_app_type] => utility
[patent_app_number] => 16/848910
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 12762
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848910
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/848910 | Compositions and uses | Apr 14, 2020 | Issued |
Array
(
[id] => 20438634
[patent_doc_number] => 12509461
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-30
[patent_title] => Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations
[patent_app_type] => utility
[patent_app_number] => 17/602025
[patent_app_country] => US
[patent_app_date] => 2020-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 5318
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602025
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602025 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations | Apr 9, 2020 | Issued |
Array
(
[id] => 17641904
[patent_doc_number] => 20220169642
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/602959
[patent_app_country] => US
[patent_app_date] => 2020-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39298
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 428
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602959
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602959 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | Apr 8, 2020 | Pending |
Array
(
[id] => 17611469
[patent_doc_number] => 20220153748
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/602770
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22028
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602770
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602770 | Pyrrolotriazine derivatives for treating kit-and PDGFRA-mediated diseases | Apr 7, 2020 | Issued |
Array
(
[id] => 17539853
[patent_doc_number] => 11304957
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-19
[patent_title] => Substituted quinazolines for inhibiting kinase activity
[patent_app_type] => utility
[patent_app_number] => 16/843610
[patent_app_country] => US
[patent_app_date] => 2020-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46246
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843610
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/843610 | Substituted quinazolines for inhibiting kinase activity | Apr 7, 2020 | Issued |
Array
(
[id] => 16206505
[patent_doc_number] => 20200239495
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, AND APPLICATIONS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/839563
[patent_app_country] => US
[patent_app_date] => 2020-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 444
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839563
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/839563 | 2-carboxypenam compound or salt thereof, pharmaceutical composition containing novel 2-carboxypenam compound or salt thereof, and applications thereof | Apr 2, 2020 | Issued |
Array
(
[id] => 17640574
[patent_doc_number] => 20220168312
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => MULTICOMPONENT CRYSTAL FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/600860
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17600860
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/600860 | MULTICOMPONENT CRYSTAL FORMULATIONS | Apr 1, 2020 | Abandoned |
Array
(
[id] => 16506151
[patent_doc_number] => 20200385407
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/839064
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839064
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/839064 | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof | Apr 1, 2020 | Issued |
Array
(
[id] => 17292182
[patent_doc_number] => 20210388021
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => POLYPODOSIDE SWEET FLAVOR MODIFIER
[patent_app_type] => utility
[patent_app_number] => 17/291814
[patent_app_country] => US
[patent_app_date] => 2020-04-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21643
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17291814
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/291814 | Polypodoside sweet flavor modifier | Mar 31, 2020 | Issued |
Array
(
[id] => 16296157
[patent_doc_number] => 20200281880
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA
[patent_app_type] => utility
[patent_app_number] => 16/836870
[patent_app_country] => US
[patent_app_date] => 2020-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20987
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836870
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/836870 | Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria | Mar 30, 2020 | Issued |
Array
(
[id] => 16267404
[patent_doc_number] => 20200268891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => Pharmaceutical Compositions Having Improved Storage Stability
[patent_app_type] => utility
[patent_app_number] => 16/834565
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11738
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16834565
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/834565 | Pharmaceutical compositions having improved storage stability | Mar 29, 2020 | Issued |
Array
(
[id] => 16628650
[patent_doc_number] => 20210047303
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-18
[patent_title] => ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/833020
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13322
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833020
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/833020 | Alkyne substituted quinazoline compound and methods of use | Mar 26, 2020 | Issued |
Array
(
[id] => 16421867
[patent_doc_number] => 20200347065
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => SALTS OF TAM INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/823751
[patent_app_country] => US
[patent_app_date] => 2020-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28627
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823751
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823751 | Salts of TAM inhibitors | Mar 18, 2020 | Issued |
Array
(
[id] => 18302853
[patent_doc_number] => 11624751
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-11
[patent_title] => Biomarkers for vitiligo
[patent_app_type] => utility
[patent_app_number] => 16/823085
[patent_app_country] => US
[patent_app_date] => 2020-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 52648
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823085
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823085 | Biomarkers for vitiligo | Mar 17, 2020 | Issued |
Array
(
[id] => 18172645
[patent_doc_number] => 11572341
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-07
[patent_title] => Biguanide compound and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/820860
[patent_app_country] => US
[patent_app_date] => 2020-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14865
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 214
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16820860
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/820860 | Biguanide compound and use thereof | Mar 16, 2020 | Issued |